• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.

作者信息

Mairinger Fabian, Vollbrecht Claudia, Mairinger Thomas, Popper Helmut

出版信息

J Thorac Oncol. 2013 Aug;8(8):e80-2. doi: 10.1097/JTO.0b013e31829b1cf9.

DOI:10.1097/JTO.0b013e31829b1cf9
PMID:23857409
Abstract
摘要

相似文献

1
The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.评估预测培美曲塞为基础的化疗后恶性胸膜间皮瘤预后生物标志物的研究问题。
J Thorac Oncol. 2013 Aug;8(8):e80-2. doi: 10.1097/JTO.0b013e31829b1cf9.
2
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.培美曲塞治疗非小细胞肺癌和恶性胸膜间皮瘤患者中 TS、DHFR 和 GARFT 的表达。
Anticancer Res. 2010 Oct;30(10):4309-15.
3
Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.胸苷酸合成酶、还原叶酸载体和多谷氨酸合成酶与培美曲塞治疗恶性胸膜间皮瘤患者的生存相关。
J Thorac Oncol. 2013 May;8(5):644-53. doi: 10.1097/JTO.0b013e318287c224.
4
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma.“一种标志物并不适用于所有情况”：需要开展更多的转化研究和验证研究，以确定间皮瘤中培美曲塞活性的可靠预测指标。
J Thorac Oncol. 2013 Aug;8(8):e79-80. doi: 10.1097/JTO.0b013e318293e45b.
5
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.间皮瘤患者中TS、MTHFR和ERCC1基因多态性与铂类联合培美曲塞一线化疗疗效的相关性
Clin Lung Cancer. 2014 Nov;15(6):455-65. doi: 10.1016/j.cllc.2014.06.009. Epub 2014 Aug 15.
6
Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.培美曲塞（力比泰、MTA、多靶点抗叶酸制剂、LY231514）用于治疗恶性胸膜间皮瘤。
Semin Oncol. 2003 Aug;30(4 Suppl 10):32-6. doi: 10.1016/s0093-7754(03)00283-5.
7
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.胸苷酸合成酶和切除修复交叉互补组 1 作为预测培美曲塞/卡铂治疗间皮瘤患者反应的标志物。
Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873. Epub 2011 Jan 24.
8
[Medical treatment of malignant pleural mesothelioma. Role of pemetrexed in current treatment].[恶性胸膜间皮瘤的医学治疗。培美曲塞在当前治疗中的作用]
Rev Pneumol Clin. 2005 Sep;61(4 Pt 2):4S10-3.
9
Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.培美曲塞（力比泰）：改善恶性胸膜间皮瘤的治疗效果。
Expert Rev Anticancer Ther. 2004 Jun;4(3):361-8. doi: 10.1586/14737140.4.3.361.
10
Pemetrexed for diffuse malignant pleural mesothelioma.培美曲塞用于弥漫性恶性胸膜间皮瘤。
Semin Oncol. 2002 Apr;29(2 Suppl 5):30-5. doi: 10.1053/sonc.2002.30765.

引用本文的文献

1
The Immunological Landscape of M1 and M2 Macrophages and Their Spatial Distribution in Patients with Malignant Pleural Mesothelioma.恶性胸膜间皮瘤患者中M1和M2巨噬细胞的免疫格局及其空间分布
Cancers (Basel). 2023 Oct 24;15(21):5116. doi: 10.3390/cancers15215116.
2
Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.间皮素表达重塑了免疫基质肿瘤微环境，预测了恶性胸膜间皮瘤患者的死亡风险。
Front Immunol. 2023 Oct 12;14:1268927. doi: 10.3389/fimmu.2023.1268927. eCollection 2023.
3
One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
三分之一的恶性胸膜间皮瘤表现出高水平的 MSLN 或 CXCR4 的免疫组织化学表达，这表明它们是内放射治疗的潜在候选者。
Int J Mol Sci. 2023 Mar 28;24(7):6356. doi: 10.3390/ijms24076356.
4
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.免疫组化可检测到的金属硫蛋白在恶性胸膜间皮瘤中的表达与铂类化疗早期失败密切相关。
Oncotarget. 2018 Apr 27;9(32):22254-22268. doi: 10.18632/oncotarget.24962.
5
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.微小RNA在MDM2阳性和阴性恶性胸膜间皮瘤之间存在差异调节。
Oncotarget. 2016 Apr 5;7(14):18713-21. doi: 10.18632/oncotarget.7666.
6
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.MDM2是恶性胸膜间皮瘤铂类培美曲塞治疗的重要预后和预测因素，而P14/ARF（由CDKN2A编码）的失调似乎导致了MDM2驱动的P53失活。
Br J Cancer. 2015 Mar 3;112(5):883-90. doi: 10.1038/bjc.2015.27. Epub 2015 Feb 10.